Pharmacology, Toxicology and Pharmaceutical Science
Cannabinoid
100%
Adverse Event
87%
Tolerability
66%
Parkinson's Disease
66%
Clinical Trial
66%
Tetrahydrocannabinol
58%
Nabiximols
36%
Observational Study
33%
Open-Label Trial
33%
Pandemic
33%
Cannabidiol
31%
Clinical Research
20%
Randomized Clinical Trial
16%
Dizziness
13%
Dronabinol
11%
Coronavirinae
10%
Side Effect
6%
Somnolence
6%
Xerostomia
6%
Medicine and Dentistry
Parkinson's Disease
100%
Clinical Trial
88%
COVID-19
55%
Systematic Review
37%
Parkinson's Disease Clinical Trial
33%
Adverse Event
33%
middle age
33%
Meta-Analysis
33%
Cannabinoid
33%
Medicine
29%
Clinical Research
20%
Tetrahydrocannabinol
14%
Social Interaction
11%
Critical Appraisal
11%
Checklist
11%
Psychological Well-Being
10%
Coronavirinae
10%
Randomized Clinical Trial
7%
Nabiximols
7%
Dizziness
7%
Nursing and Health Professions
Parkinson's Disease
100%
Systematic Review
40%
Meta Analysis
33%
Pandemic
33%
Adverse Event
33%
Confidence Interval
26%
Tetrahydrocannabinol
26%
CINAHL
14%
Dizziness
13%
Nabiximols
13%
Side Effect
13%
Electronic Device
10%
Embase
8%
Thematic Analysis
8%
Critical Appraisal
8%
Checklist
8%
Dronabinol
6%
Xerostomia
6%
Somnolence
6%
Medline
6%
Cochrane Library
6%
Effect Size
6%
Cannabidiol
6%
